Prescribing in type 2 diabetes patients with and without cardiovascular disease history: A descriptive analysis in the UK CPRD by Farmer, Ruth E et al.
Clinical Therapeutics/Volume xxx, Number xxx, xxxxPrescribing in Type 2 Diabetes Patients With and
Without Cardiovascular Disease History: a Descriptive
Analysis in the UK CPRDRuth E. Farmer, PhD1; Ivan Beard, PGDip1; Syed I. Raza, MSc, BPharm1;
Nicholas D. Gollop, MBBCh, BSc2; Niraj Patel, MBBS1,*;
Abigail Tebboth, MSci1; Andrew P. McGovern, MD(Res)3;
Naresh Kanumilli, MBBS MRCGP4; and Andrew Ternouth, PhD1
1Boehringer Ingelheim Ltd, Bracknell, United Kingdom; 2Boehringer Ingelheim GmbH,
Ingelheim Am Rhein, Germany; 3University of Exeter Medical School, Institute of Biomedical
and Clinical Science, University of Exeter, Exeter, Devon, United Kingdom; and 4Northenden
Group Practice, Manchester, United KingdomAccepted for publication December 20, 2020
https://doi.org/10.1016/j.clinthera.2020.12.015
0149-2918/$ - see front matterABSTRACT
Purpose: Some classes of glucose-lowering
medications, including sodium-glucose co-transporter
2 inhibitors (SGLT2is) and glucagon-like peptide 1-
receptor agonists (GLP1-RAs) have cardio-protective
benefit, but it is unclear whether this influences
prescribing in the United Kingdom (UK). This study
aims to describe class-level prescribing in adults with
type 2 diabetes mellitus (T2DM) by cardiovascular
disease (CVD) history using the Clinical Practice
Research Datalink (CPRD).
Methods: Four cross-sections of people with T2DM
aged 18e90 and registered with their general practice
for >1 year on 1st January 2017 (n ¼ 166,012), 1st
January 2018 (n ¼ 155,290), 1st January 2019 (n ¼
152,602) and 31st December 2019 (n ¼ 143,373)
were identified. Age-standardised proportions for
class use through time were calculated separately in
those with and without CVD history and by total
number of medications prescribed (one, two, three,
four+). An analysis by UK country was also performed.
Findings: Around 31% of patients had CVD
history at each cross-section. Metformin was the
most common treatment (>70% of those with and
without CVD had prescriptions across all treatment
lines). Overall use of SGLT2is and GLP1-RAs was
low, with slightly less use in patients with CVD
(SGLT2i: 9.8% and 13.8% in those with and
without CVD respectively; GLP1-RA: 4.3% and* Current affiliation: TEVA pharmaceuticals
▪▪▪ xxxx4.9%, December 2019). Use of SGLT2is as part of
dual therapy was low but rose throughout the study.
In January 2017, estimated use was 8.0% (95% CI
6.9e9.1%) and 8.9% (8.6e9.3%) in those with and
without CVD. By December 2019 this reached
18.3% (17.0e19.5%) and 21.2% (20.6e21.7%) for
those with and without CVD respectively. SGLT2i
use as triple therapy increased: 22.7% (21.0e24.4%)
and 25.9% (25.2e26.6%) in January 2017 to 41.3%
(39.5e43.0%) and 45.5% (44.7e46.3%) in
December 2019. GLP1-RA use also increased, but
observed usage remained lower than SGLT2
inhibitors. Insulin use remained stable throughout,
with higher use observed in those with CVD (16% vs
9.7% Dec 2019). Time trends in England, Wales,
Scotland and Northern Ireland were similar, although
class prevalence varied.
Implications: Although use of SGLT2is and GLP1-
RAs has increased, overall usage remains low with
slightly lower use in those with CVD history,
suggesting there is opportunity to optimise use of
these medicines in T2DM patients to manage CVD
risk. Insulin use was substantially more prevalent in
those with CVD despite no evidence of CVD benefit.
Further investigation of factors influencing this
finding may highlight strategies to improve patient© 2021 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1
Clinical Therapeuticsaccess to the most appropriate treatments, including
those with evidence of cardiovascular benefit. (Clin
Ther. xxxx;xxx:xxx) © 2021 The Authors. Published
by Elsevier Inc. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/
4.0/).
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betes mellitus.INTRODUCTION
Cardiovascular disease (CVD) is a common
comorbidity of type 2 diabetes mellitus (T2DM)
globally1 as well as in the United Kingdom, with
~35% of people with T2DM estimated to have
CVD.2 Recently, large-scale cardiovascular outcome
trials have reported that sodium-glucose co-
transporter 2 (SGLT2) inhibitors and glucagon-like
peptide 1-receptor agonists (GLP1-RAs) have
significant cardioprotective benefits in people with
T2DM3e13 in addition to metabolic benefits such as
blood pressure control and weight loss.14,15 The first
of these trials, EMPA-REG OUTCOME
(Empagliflozin Cardiovascular Outcome Event Trial
in Type 2 Diabetes Mellitus Patients),3 was published
in 2015, with the remaining trials reported between
2016 and 2019. For the SGLT2 inhibitors, the
EMPA-REG OUTCOME and CANVAS
(Canagliflozin Cardiovascular Assessment Study)
trials both showed a significant reduction in the
primary end point of 3-point major adverse
cardiovascular events (MACE), including CV death,
nonfatal myocardial infarction, and nonfatal stroke,
in a population with T2DM and increased risk for
CVD, and empagliflozin showed a significant
reduction in cardiovascular death.3,4 The DECLARE-
TIMI-58 (Dapagliflozin Effect on Cardiovascular
EventseThrombolysis in Myocardial Infarction 58)
and VERTIS-CV (Cardiovascular Outcomes
Following Ertugliflozin Treatment in Diabetes
Mellitus Participants With Vascular Disease) trials
showed noninferiority in 3-point MACE, but did not
show superiority, versus placebo.5 All SGLT2
inhibitors showed a significant reduction in
hospitalization for heart failure and the composite
end point of hospitalization for heart failure or
cardiovascular death.3e6 For the GLP1-RAs, 4 of the2
7 cardiovascular outcome trials (LEADER
[Liraglutide Effect and Action in Diabetes],
SUSTAIN-6 [Trial to Evaluate Cardiovascular and
Other Long-term Outcomes With Semaglutide in
Subjects With Type 2 Diabetes], HARMONY
Outcomes, and REWIND [Researching
Cardiovascular Events with a Weekly Incretin in
Diabetes]) have shown significant reductions in 3-
point MACE.7e13
As a result of these trials, the focus of international
guidelines for T2DM has started to shift beyond a sole
emphasis on glycemic control to managing the
cardiovascular complications of diabetes, beginning
with the 2018 consensus report by the American
Diabetes Association (ADA)/European Association
for the Study of Diabetes (EASD) and the 2019
European Society for Cardiology guidelines.16e19 At
the time of writing, the National Institute for Health
and Care Excellence (NICE) do not include
consideration of CVD history or risk in their
treatment guideline, although data from the
cardiovascular outcome trials are under review, and a
guideline update is expected.20
The ADA/EASD and the European Society for
Cardiology guidelines recommend that prescribers
consider early use of medication with demonstrated
CVD benefit in people with high CVD risk.18,19
However, it is unclear if and how treatment patterns
are changing to reflect these updated
recommendations. In particular, the use of treatment
classes with cardioprotective benefit in patients with
T2DM is unknown, including extent of use and stage
of initiation, as well as how use varies between those
with and without CVD.
Although data exist on prescribing patterns for
diabetes, existing studies do not stratify according to
CVD history,21,22 or do not reflect the period post-
2017, during which the evidence of CVD benefit for
SGLT2 inhibitors and GLP1-RAs has begun to
accrue.23
The goal of the present study was to describe
prescribing of glucose-lowering medications, over 4
years since 2017, in people with T2DM with and
without a history of CVD in the United Kingdom.
The main interest was whether the presence of CVD
history seems to influence prescribing over time, in
light of the new evidence and updated guidelines.Volume xxx Number xxx
R.E. Farmer et al.PATIENTS AND METHODS
Study Design
This observational cohort study included nested
cross-sectional analyses. Data were taken from the
Clinical Practice Research Datalink (CPRD; https://
www.cprd.com/) using CPRD GOLD. The CPRD
holds de-identified data from 50 million patients in
general practices across the United Kingdom and is a
well-recognized source for publications on the use of
medicines. The research was approved under
Independent Scientific Advisory Committee protocol
number 20_061A.
Population
The population of interest was adults with a T2DM
code contributing at least 1 day of eligible data to the
CPRD during the study period (January 1,
2017eDecember 31, 2019). T2DM was defined as a
relevant diagnosis code at any time in the patient's
record before the end of the study (see Supplemental
Table I in the online version at
doi:XXXXXXXXXX). Included individuals also had
to have no prescription for insulin in the first 6
months of diabetes diagnosis, be aged >18 years, and
have nonmissing data on their sex. All patients also
had to have research-acceptable data, a metric
defined by CPRD based on the quality of the patient
record and the practice's data recording.
Patients were eligible to contribute data from their
index date, defined as the latter of: January 1, 2017;
first T2DM record; one year after practice data were
considered research standard; or one year after
patient registration (see Supplemental Fig. 1 in the
online version at doi:XXXXXXXXXX). This ensured
at least 1 year of accrued data for all individuals in
the cohort before their index date. Patients were
censored from the cohort at the earliest of: transfer
out of practice; date of death; last collection date for
the practice; or end of study period (December 31,
2019). Four cross-sectional populations were
identified from the base cohort, consisting of those
alive and under follow-up (as defined earlier) on the
following: January 1, 2017; January 1, 2018;
January 1, 2019; and December 31, 2019. This was
to emulate four annual “audits” within all practices
contributing to the CPRD on these dates, thus
providing representative denominators for estimating▪▪▪ xxxxthe point prevalence for use of each medication class
of interest. Patients were excluded at this point for
the following: recent type 1 diabetes, secondary, or
gestational diabetes codes; evidence of pregnancy; or
age 90 years at the cross-section date.
Outcomes and Covariates
The outcome of interest was prescription of any of
the following classes of routinely used glucose-
lowering medication at the cross-section date:
biguanides/metformin, sulfonylureas (SUs), dipeptidyl
peptidase-4 (DPP4) inhibitors (including sitagliptin,
saxagliptin, alogliptin, linagliptin, vildagliptin, and
combinations), SGLT2 inhibitors (including
dapagliflozin, empagliflozin, canagliflozin,
ertugliflozin, and combinations), thiazolidinediones,
GLP1-RAs (including dulaglutide, semaglutide,
exenatide, liraglutide, lixisenatide, and albiglutide),
insulin, and other (acarbose and glinides). A full list
of product codes is available in the Supplemental
Information in the online version at
doi:XXXXXXXXXX. A prescription was assumed to
be current if the number of days' supply (calculated
by using data on quantity and daily dose where
specified, detailed in the Supplemental Information in
the online version at doi:XXXXXXXXXX) plus a
grace period equal to the number of days' supply,
was sufficient to cover the period up to the cross-
section date. If number of days’ supply was missing,
a 28-day supply was assumed as this was the most
frequent prescription duration when specified.
The proportion of individuals with a current
prescription for each class of glucose-lowering
medication was compared according to CVD status
at each cross-section. History of CVD was defined as
a Read code indicating any of the following before
the cross-section date: myocardial infarction, unstable
angina, coronary atherosclerosis, or other forms of
ischemic heart disease, and history of coronary artery
procedures, congestive heart failure, stroke, transient
ischemic attack, or peripheral arterial disease. All
codes are provided in the Supplemental Information
(see the online version at doi:XXXXXXXXXX). As
with any database, research quality is dependent on
the quality of data entry. It is possible that missing
data (eg, codes relating to CVD history) could lead to
a misclassification of patients in the cohort,3
Clinical Therapeuticsparticularly for binary outcomes such as CVD history.
However, patient populations with a chronic disease
such as T2DM are likely to be more closely
monitored than the general population due to the
presence of Quality and Outcomes Framework
targets. As such, missed coding of comorbidities is
likely to be less problematic than in the general
population.
Treatments prescribed were categorized into
“treatment stages” based on the total number of
distinct classes of glucose-lowering medications
concurrently prescribed (none, 1, 2, 3, or 4). For
simplicity of reporting, we also refer to those on 2
and 3 classes as being on dual and triple therapy,
respectively. A comparison according to UK
geographic region, as defined in CPRD, was also
conducted.
Other covariates of interest included age, sex,
ethnicity, most recent estimated glomerular filtration
rate (eGFR) calculated by using the Chronic Kidney
Disease Epidemiology Collaboration formula,24 and
years since diabetes diagnosis (if available). All
covariates, except for ethnicity, UK region, and sex,
were time updated for the respective cross-section
date if a patient contributed to multiple cross-
sections. The Chronic Kidney Disease Epidemiology
Collaboration formula was not adjusted for ethnicity
due to high levels of missingness; it has been
previously reported that this omission has minimal
impact on results.25 Ethnicity was determined by
using preexisting methodology for the CPRD.26
All clinical code lists that contributed to the
definition of the study population and derivation of
covariates are provided in Supplemental Table I
though XIV in the online version at
doi:XXXXXXXXXX and were reviewed by 2
clinical experts for accuracy.
Statistical Analysis
Descriptive summary statistics for each cross-section
were calculated for covariates of interest, including the
proportions of missingness. Point prevalence of
medication use by calendar year was calculated as
the proportion of individuals with a current
prescription for each class of glucose-lowering
medication at each treatment stage. Exact 95% CIs
for proportions were calculated separately according
to CVD status and treatment stage to quantify
sampling error.4
The main analysis used age-standardized prevalence
to reduce any potential confounding by an aging
cohort or by differences in age between those with
and without a history of CVD; the age distribution of
T2DM from the latest National Diabetes Audit for
England was used for the analysis.27 Age groupings
used in the standardization were <40 years, 40e64
years, 65e79 years, and 80 years.
A sensitivity analysis to test the robustness of the
definition of “current prescription” was also
performed, by changing the grace period to a fixed
30 days rather than a length of time equal to the
number of days’ supply of the medicine. A further
analysis assuming that any prescriptions in the 3
months before the cross-section date were current
was also conducted. Finally, a sensitivity analysis
restricted to patients whose most recent eGFR level
was 60 mL/min/1.73 m2 was conducted, as some
glucose-lowering medications should not be initiated
in patients with eGFR levels <60 mL/min/1.73 m2. In
this final sensitivity analysis, those with missing
eGFR data were also excluded.
All analyses were conducted by using SAS version
9.4 (SAS Institute, Inc, Cary, North Carolina) and
Stata version 15 (StataCorp, College Station, Texas).
RESULTS
Population
A total of 219,128 people with T2DM were
identified for the base cohort (Figure 1). After
applying cross-sectionespecific exclusions, there were
166,012, 155,290, 152,602, and 145,373 individuals
for the January 2017, January 2018, January 2019,
and December 2019 cross-sections, respectively.
Cohort characteristics remained broadly stable over
the 4 years of the study (Table I), including the
proportion of patients with a history of CVD (31%).
Glycosylated hemoglobin levels and body mass index
were similar across cross-sections and in those with
and without CVD history. The mean age of included
individuals was 65 years in those without CVD
history and 73 years in those with CVD.
Medication Classes Prescribed
Table II presents the number of current glucose-
lowering medication classes prescribed to each
patient according to CVD history. The proportions of
patients receiving none, 1, 2, 3, or 4 classes of
glucose-lowering medications were similar in patientsVolume xxx Number xxx
Figure 1. Population flow diagram for the overall population and cross-sections. CPRD ¼ Clinical Practice
Research Datalink; DM ¼ diabetes mellitus; T1DM ¼ type 1 diabetes mellitus; T2DM ¼ type 2
diabetes mellitus. *Valid follow-up time defined as having accrued at least 1 year of research quality
data since registration with their general practice.
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Table I. Patient demographic characteristics according to cross-section.
Characteristic 2017 (N ¼ 166,012) 2018 (N ¼ 155,290) 2019 (N ¼ 152,602) 2020 (N ¼ 145,373)
No CVD CVD No CVD CVD No CVD CVD No CVD CVD
N 115,123 50,889 107,937 47,353 105,906 46,696 100,565 44,808
Age at cross-section
Mean (SD), y 64.5 (12.5) 72.7 (10.1) 64.6 (12.5) 72.7 (10.1) 64.8 (12.5) 72.8 (10.1) 65.0 (12.5) 72.8 (10.2)
Median (IQR),
y
65.0 (56.0, 74.0) 74.0 (66.0, 81.0) 65.0 (56.0, 74.0) 74.0 (66.0, 81.0) 65.0 (56.0, 74.0) 74.0 (66.0, 81.0) 66.0 (56.0, 74.0) 74.0 (66.0, 81.0)
Male sex, no. (%) 62,260 (54.1) 31,993 (62.9) 58,567 (54.3) 29,868 (63.1) 57,541 (54.3) 29,577 (63.3) 54,627 (54.3) 28,420 (63.4)
Diabetes duration
Mean (SD), y 7.4 (5.7) 9.3 (6.5) 7.7 (5.8) 9.6 (6.7) 8.0 (6.0) 9.8 (6.8) 8.1 (6.1) 10.0 (7.0)
Median (IQR),
y
6.4 (2.9, 10.8) 8.3 (4.0, 13.3) 6.6 (3.0, 11.2) 8.6 (4.2, 13.8) 6.8 (3.1, 11.6) 8.9 (4.3, 14.3) 7.0 (3.2, 11.9) 9.0 (4.3, 14.6)
Missing, no.
(%)




31.8 (6.7) 30.8 (6.1) 31.9 (6.7) 30.8 (6.1) 31.8 (6.7) 30.7 (6.2) 31.9 (6.7) 30.8 (6.2)
Median (IQR)),
kg/m2
30.9 (27.2, 35.4) 30.0 (26.6, 34.1) 30.9 (27.2, 35.4) 30.0 (26.6, 34.1) 30.8 (27.2, 35.4) 30.0 (26.5, 34.0) 30.9 (27.3, 35.5) 30.0 (26.6, 34.1)
Missing, no.
(%)
6008 (5.2) 2917 (5.7) 6198 (5.7) 2951 (6.2) 6503 (6.1) 2944 (6.3) 6366 (6.3) 2878 (6.4)
Glycosylated hemoglobin
Mean (SD), % 7.4 (1.5) 7.4 (1.5) 7.4 (1.5) 7.4 (1.5) 7.5 (1.5) 7.4 (1.5) 7.5 (1.5) 7.5 (1.5)
Median (IQR),
%
7.0 (6.4, 8.0) 7.0 (6.4, 8.0) 7.1 (6.5, 8.1) 7.0 (6.4, 8.0) 7.1 (6.5, 8.1) 7.1 (6.5, 8.0) 7.1 (6.5, 8.2) 7.1 (6.5, 8.1)
Missing, no.
(%)









83.8 (68.2, 95.7) 69.8 (53.2, 85.3) 83.6 (67.8, 95.4) 69.7 (52.9, 85.2) 84.2 (68.4, 95.8) 70.3 (53.2, 85.9) 84.5 (68.8, 96.1) 71.2 (53.7, 86.5)
Missing, no.
(%)
6217 (5.4) 1869 (3.7) 6669 (6.2) 2143 (4.5) 7120 (6.7) 2136 (4.6) 7336 (7.3) 2312 (5.2)
Ethnicity, no. (%)
White 51,842 (45.0) 23,638 (46.5) 48,255 (44.7) 21,853 (46.1) 47,732 (45.1) 21,639 (46.3) 45,055 (44.8) 20,576 (45.9)
South Asian 4171 (3.6) 1191 (2.3) 4046 (3.7) 1112 (2.3) 3672 (3.5) 1030 (2.2) 3284 (3.3) 944 (2.1)













Table I. (Continued )
Characteristic 2017 (N ¼ 166,012) 2018 (N ¼ 155,290) 2019 (N ¼ 152,602) 2020 (N ¼ 145,373)
No CVD CVD No CVD CVD No CVD CVD No CVD CVD
Other 978 (0.8) 240 (0.5) 945 (0.9) 235 (0.5) 970 (0.9) 242 (0.5) 900 (0.9) 223 (0.5)
Mixed 438 (0.4) 69 (0.1) 428 (0.4) 65 (0.1) 411 (0.4) 62 (0.1) 399 (0.4) 64 (0.1)
Missing 56,161 (48.8) 25,502 (50.1) 52,818 (48.9) 23,856 (50.4) 51,958 (49.1) 23,532 (50.4) 49,883 (49.6) 22,827 (50.9)
UK geographic region, no. (%)
North East 669 (0.6) 395 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
North West 6233 (5.4) 2785 (5.5) 5615 (5.2) 2453 (5.2) 5764 (5.4) 2508 (5.4) 5764 (5.7) 2489 (5.6)
Yorkshire and
Humberside
757 (0.7) 311 (0.6) 238 (0.2) 93 (0.2) 244 (0.2) 99 (0.2) 252 (0.3) 101 (0.2)
West Midlands 7682 (6.7) 2867 (5.6) 6551 (6.1) 2409 (5.1) 6433 (6.1) 2359 (5.1) 5023 (5.0) 1903 (4.2)
East of England 2122 (1.8) 1031 (2.0) 1585 (1.5) 609 (1.3) 513 (0.5) 248 (0.5) 245 (0.2) 137 (0.3)
South West 4342 (3.8) 1794 (3.5) 3023 (2.8) 1212 (2.6) 2481 (2.3) 971 (2.1) 1658 (1.6) 675 (1.5)
South Central 4871 (4.2) 1570 (3.1) 3421 (3.2) 1094 (2.3) 2884 (2.7) 922 (2.0) 1266 (1.3) 428 (1.0)
London 6415 (5.6) 2098 (4.1) 5964 (5.5) 1936 (4.1) 4442 (4.2) 1512 (3.2) 3490 (3.5) 1183 (2.6)
South East
Coast
11,506 (10.0) 4152 (8.2) 10,246 (9.5) 3628 (7.7) 9886 (9.3) 3449 (7.4) 7457 (7.4) 2474 (5.5)
Northern
Ireland
6163 (5.4) 3415 (6.7) 6428 (6.0) 3531 (7.5) 6735 (6.4) 3677 (7.9) 6976 (6.9) 3756 (8.4)
Scotland 35,146 (30.5) 17,177 (33.8) 35,212 (32.6) 17,036 (36.0) 35,879 (33.9) 17,410 (37.3) 36,962 (36.8) 17,838 (39.8)
Wales 29,217 (25.4) 13,294 (26.1) 29,654 (27.5) 13,352 (28.2) 30,645 (28.9) 13,541 (29.0) 31,472 (31.3) 13,824 (30.9)
CVD subtypes, no. (%)
Angina e 17,463 (10.5) e 47,353 (30.5) e 46,696 (30.6) e 14,302 (9.8)
MI e 13,500 (8.1) e 15,810 (10.2) e 15,222 (10.0) e 12,138 (8.3)
Heart failure e 9606 (5.8) e 12,715 (8.2) e 12,630 (8.3) e 9101 (6.3)
Other IHD e 24,968 (15.0) e 9165 (5.9) e 9308 (6.1) e 20,715 (14.2)
Coronary
procedure
e 11,806 (7.1) e 22,701 (14.6) e 21,969 (14.4) e 10,449 (7.2)
PAD e 8930 (5.4) e 11,056 (7.1) e 10,911 (7.1) e 7648 (5.3)
Stroke e 12,271 (7.4) e 8156 (5.3) e 7949 (5.2) e 11,250 (7.7)
TIA e 6417 (3.9) e 11,679 (7.5) e 11,719 (7.7) e 5772 (4.0)
Unspecified e 5180 (3.1) e 5985 (3.9) e 5979 (3.9) e 4449 (3.1)
CVD ¼ cardiovascular disease; IHD ¼ ischemic heart disease; IQR ¼ interquartile range; MI ¼ myocardial infarction; PAD ¼ peripheral arterial disease; TIA ¼ transient






































































































































































































































































































































































































with or without CVD history. Changing the definition
of current use in the sensitivity analyses had a
negligible impact on the proportions (see
Supplemental Tables XV and XVI in the online
version at doi:XXXXXXXXXX). Approximately
30% of the included patients had no current
prescriptions for any glucose-lowering therapy;
patient characteristics for this group are provided in
Supplemental Table XVII in the online version at
doi:XXXXXXXXXX.
Overall, as expected, the most commonly used
glucose-lowering medication across all treatment
stages was metformin (Table III), followed by SUs
and DPP4 inhibitors. Use of both the SGLT2
inhibitor and GLP1-RA classes increased through
time but remained low compared with the
aforementioned classes, irrespective of CVD status.
Figure 2 presents the age-standardized proportions
of patients receiving each class of glucose-lowering
therapy at each cross-section according to history of
CVD. Results are shown separately according to the
total number of classes prescribed. “Other classes”
were excluded from the figures because the
proportion of patients taking these was <1%
(Table III). Tabulated point estimates with 95% CIs
and noneage-standardized results are presented in
the Supplemental Information in the online version at
doi:XXXXXXXXXX.
Metformin was the most common monotherapy,
with >70% of monotherapy patients with and
without a history of CVD having a current
prescription. This finding remained consistent
throughout the study period. Use of SUs declined
since 2017 in patients with and without CVD. DPP4
inhibitor use increased for dual therapy and remained
broadly constant at ~55% for triple therapy, with
little difference between those with and without CVD
history.
Use of SGLT2 inhibitors increased over time for all
stages other than monotherapy. Again, there was little
difference between patients with and without a history
of CVD; although there appears to be slightly lower
use in people with a history of CVD, the differences
are small. In January 2017, SGLT2 inhibitor use as
dual therapy was estimated to be 8.0% (95% CI,
6.9e9.1) in those with a history of CVD and 8.9%
(95% CI, 8.6e9.3) in those without CVD. By
December 2019, this had increased to 18.3% (95%
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▪▪▪ xxxxthose with and without CVD, respectively. In those
taking 3 classes of medication, use of SGLT2
inhibitors was at 22.7% (95% CI, 21.0e24.4) and
25.9% (95% CI, 25.2e26.6) at the beginning of
2017 for those with/without CVD, increasing to
41.3% (95% CI, 39.5e43.0) and 45.5% (95% CI,
44.7e46.3) in December 2019 (Figure 2).
GLP1-RAs exhibited smaller changes through time,
with the proportion of patients on this class of
medication ~6% for dual therapy and ~17% for
triple therapy in December 2019. Use of
thiazolidinediones remained constant over time for
those with and without CVD. The only class of
medication to show differences according to CVD
history was insulin, with greater use observed in
patients with a history of CVD at all treatment
stages. In December 2019, the proportion of patients
on insulin as monotherapy was 15% (95% CI,
14.1e15.9) in those with CVD and 8.2% (95% CI,
7.9e8.5) in those without. Analogous proportions
for dual and triple therapy were 25.5% (95% CI,
24.5e26.4) and 16.2% (95% CI, 15.7e16.7),
respectively, in those with CVD history, and 29.3%
(95% CI, 27.7e30.8) and 19.4% (95% CI,
18.6e20.1) in those without (Figure 2).
Results According to Country
Similar trends over time were observed across
England, Wales, Scotland, and Northern Ireland,
although the prevalence of different classes varied
(see Supplemental Figs. 3 and 4 in the online version
at doi:XXXXXXXXXX). For example, use of SUs in
those on dual therapy was estimated to be higher in
Scotland than in other countries, and lower in
Northern Ireland (see Supplemental Fig. 3 in the
online version at doi:XXXXXXXXXX).
Use of GLP1-RAs in dual therapy was comparable
across all countries and CVD history, remaining
below 10% at the end of 2019. For triple therapy,
the data suggest that use of GLP1-RAs has not
increased at the same speed as SGLT2 inhibitors
since 2017, with usage still below 20% at the end of
2019 in the majority of country/CVD status strata
(Figure 3; Supplemental Figs. 3 and 4 in the online
version at doi:XXXXXXXXXX).
Use of SGLT2 inhibitors was observed to be
highest in Northern Ireland. By the end of 2019, in
patients with no history of CVD, 29.5% (95% CI,
27.3e31.7) and 51.1% (95% CI, 47.9e54.1) of9
Figure 2. Age-standardized proportions of current classes used according to cardiovascular disease (CVD)
status and total number of currently prescribed glucose-lowering medication classes.
DPP4i ¼ dipeptidyl peptidase-4 inhibitors; GLP1-RA ¼ glucagon-like peptide 1-receptor agonists;
SGLT2i ¼ sodium-glucose co-transporter 2 inhibitors; TZD ¼ thiazolidinediones.
Clinical Therapeuticsindividuals on dual and triple therapy, respectively,
had a current prescription for an SGLT2 inhibitor.
The analogous proportions in those with a history
of CVD were slightly lower, a trend that was also
observed for other countries, although in many
cases the absolute observed differences were small
(Figure 3). England had the lowest estimated
proportion of patients with CVD currently taking
an SGLT2 inhibitor as both dual and triple therapy.
Regional analysis within England was condensed to
the North, West Midlands, East of England, South
West and Central, and London and Southeast due to
data sparsity. Crude results for this analysis are
provided in the Supplemental Information in the
online version at doi:XXXXXXXXXX. Small
variations in prescribing between regions were10observed; however, the small numbers resulted in
wide CIs, making interpretation difficult.
Results in Patients With eGFR Levels ≥60 mL/
min/1.73 m2
Those with eGFR levels 60 mL/min/1.73 m2
were slightly younger, had shorter duration of
diabetes, and were slightly less likely to have a
history of CVD compared with the overall
population (25% vs 31%) (see Supplemental
Table XIX and XX in the online version at
doi:XXXXXXXXXX). Overall, results were similar
to those seen in the main analysis, again with
little difference between those with and without aVolume xxx Number xxx
Figure 3. Age-standardized proportion (95% CI) of people with type 2 diabetes mellitus (T2DM) receiving
sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1-receptor agonists
(GLP1-RA) as part of dual or triple therapy according to UK country in December 2019.
CVD ¼ cardiovascular disease.
R.E. Farmer et al.history of CVD. The observed proportion of
patients using SGLT2 inhibitors was consistently
between 1 and 6 percentage points higher in those
with eGFR levels 60 mL/min/1.73 m2, with a
maximum observed usage of just below 50% of
those on triple therapy in December 2019,
regardless of CVD status (see Supplemental Fig. 5
in the online version at doi:XXXXXXXXXX).DISCUSSION
Overall, between 2017 and 2020, there has been a shift
in prescribing glucose-lowering medication
characterized by reduced usage of SUs, and increased
usage of newer classes, SGLT2 inhibitors and GLP1-
RAs, with greater increases observed for SGLT2
inhibitors. As expected, metformin remains the most
frequently prescribed medication as monotherapy and
in combination with other therapies as per NICE
guideline NG28.20 The common use of metformin,
decrease in use of SUs, and increase in use of SGLT2
inhibitors are broadly consistent with trends reported
in other studies of prescribing in UK patients with
T2DM, although use of GLP1-RAs seem to be higher
in our study than previously reported.21,22▪▪▪ xxxxApproximately 30% of people included in our study
had a history of CVD; this finding was consistent
across all years of the study and agrees with findings
from 2 other recent studies of patients with T2DM
and history of CVD in the United Kingdom and
Scotland.2,23
At a population level, the data provide limited
evidence of differences in prescribing of glucose-
lowering medications based on a history of CVD.
Although there were some differences, (eg, less use
of metformin as monotherapy, slightly lower use of
SGLT2 inhibitors in patients with a history of
CVD), these absolute differences were small and had
little impact on the overall proportions of
medications prescribed. The most notable difference
was observed for insulin, with greater use in patients
with a history of CVD. Age standardization and the
sensitivity analysis in patients with eGFR levels
>60 mL/min/1.73 m2 suggest that these findings are
not explained by older age or renal impairment. The
prescribing patterns we observed are consistent with
a previous study examining CVD prevalence and
risk factors in people with T2DM in Scotland in
2016, which also found high usage of metformin but11
Clinical Therapeuticslow use of SGLT2 inhibitors and GLP1-RAs, the
classes that have been shown to reduce CVD risk
and mortality.23
Although use of SGLT2 inhibitors and GLP1-RAs
increased throughout the study period, use of these
classes remained low overall. Of all adults with
T2DM sampled, only 12.5% and 4.7% overall
(9.8% and 4.3% in those with a history of CVD)
had a current prescription for an SGLT2 inhibitor or
GLP1-RA, respectively, in December 2019. In
addition, the proportion of individuals on dual
therapy receiving these classes remained low
compared with those receiving triple therapy,
suggesting a delay in use of these treatments to later
stages of the treatment pathway. SGLT2 inhibitors
and GLP1-RAs are the only classes that show
reductions in MACE. As such, the lack of observed
differences in prescribing of these classes between
those with and without a history of CVD may
suggest that UK practice has not yet been able to
change to reflect the new evidence and guideline
recommendations, such as those from the ADA and
the EASD.16,18
This lack of change may occur for a number of
reasons. First, it could reflect a more historical
viewpoint that medications for T2DM are used for
controlling glucose levels, rather than other end
points observed in randomized controlled trials.
There may be a lack of understanding of the results
of the cardiovascular outcomes trials for the SGLT2
inhibitors and GLP1-RAs, including their
implications for clinical practice. It could be that UK
clinical practices are following the current NICE
guideline, which has not yet been updated to include
the results of the previously mentioned cardiovascular
outcome trials.20 Alternatively, it could be that
medication formularies have not been updated to
reflect the latest evidence, and thus a barrier to
physicians prescribing the SGLT2 inhibitors and
GLP1-RAs exists. Finally, there may be individual
patient contraindications or tolerability issues
preventing the use of these classes, which mask any
shift in prescribing behavior at the population level.
It is worth noting that the population with history of
CVD in our study is considerably older, and with
lower eGFR levels, than the population enrolled in
cardiovascular outcomes trials, which may have
affected prescribers’ decisions.12This study was not designed to identify the drivers
for these prescribing decisions, although a sensitivity
analysis in those with an eGFR level 60 mL/min/
1.73 m2 provided similar results, suggesting that the
increased risk of renal impairment (a key
contraindication for some classes of glucose-lowering
medication) in those with a history of CVD does not
explain our findings. Other determining factors are
clearly important if we are to understand if treatment
of T2DM at both the patient and population level in
the United Kingdom is optimal. Further research is
ongoing to describe and compare the characteristics
of those initiating different classes of glucose-
lowering medication by CVD history as well as by
treatment stage, including which characteristics seem
to be associated with medication choice.
Similarly to a previous study,23 we observed greater
insulin use in people with a history of CVD compared
with those without CVD history. This finding may be a
result of older research that suggested insulin use was
beneficial in patients after a myocardial infarction,28
although these findings were not replicated in a
subsequent study and the previous findings are likely
to have been due to good glycemic control rather
than intensive insulin use.29,30 More recently, SGLT2
inhibitors have shown further benefits in people with
heart failure without diabetes.31,32 Whether this
scenario further increases uptake in the subset of
T2DM patients with comorbid heart failure, and also
if it encourages prescribers to move away from
insulin in patients with a history of CVD, will be an
important subject for future research.
The overall UK trends were reflected in each country
included in the study (England, Scotland, Wales, and
Northern Ireland), but there were small differences in
terms of proportions prescribed for each class, with
England showing the lowest usage of SGLT2
inhibitors. This may be due to clinicians in each
devolved nation following different guidelines, or it
could be due to other clinical considerations.
Investigating the factors affecting prescribing
decisions in each country may show unwarranted
variations and reveal ways in which these could be
addressed.
Although there are a number of possible reasons
why patients may not be prescribed SGLT2 inhibitors
and GLP1-RAs, the evidence of their benefits in CVD
risk reduction for patients with T2DM has now been
accumulating for >5 years. RandomizedVolume xxx Number xxx
R.E. Farmer et al.cardiovascular outcome trials are now supported by
real-world evidence studies such as CVD-REAL
(Comparative Effectiveness of Cardiovascular
Outcomes in New Users of SGLT-2 Inhibitors) and
EMPRISE (Empagliflozin Comparative Effectiveness
and Safety), which show that the reductions in
mortality and hospitalization for heart failure seen in
clinical trials are consistent in the real world.33,34
SGLT2 inhibitors have been assessed and found to be
cost-effective by NICE in monotherapy and in
combination therapy, and are therefore recommended
as treatment options.35e41 The GLP1-RAs have not
undergone NICE technology appraisals but are
recommended as triple therapy in NICE guideline
NG28.20 Both medication classes have been in use
for a number of years and have well-understood
safety profiles; thus, it is unlikely that prescriptions
should be limited by concerns related to adverse
events, although there may be individual
contraindications or intolerances.
It is difficult to determine a specific proportion of
patients who should be prescribed either an SGLT2
inhibitor or GLP1-RA, as their use should be
considered in discussion with patients’ health care
professionals, leading to individualized treatment
decisions. There is a proportion of patients for whom
these classes will not be appropriate, although this is
difficult to quantify. However, it is important that
practitioners consider the presence of CVD in their
selection of glucose-lowering medication and in
particular consider the use of these 2 classes with
demonstrable CVD benefit in this group of patients.
The data we present here suggest this is currently not
the case and therefore highlight a key area of practice
that is not keeping pace with the current clinical
evidence. Published literature suggests that 65% of
men and 68% of women with T2DM have 2 risk
factors for CVD.23 In addition, 67% of men and
58% of women with T2DM are expected to develop
CVD by 80 years of age.42 This information suggests
that the proportion of people with T2DM, with or
without CVD, receiving SGLT2 inhibitors and GLP1-
RAs should perhaps be higher than we observed.
A major strength of the present analysis is that it
used real-world data from a validated source of
primary care records. The CPRD has previously been
shown to be representative of the UK population in▪▪▪ xxxxterms of age, sex, and ethnicity.43 The CPRD also
conducts basic quality checks on data before release;
this fact, and the use of only research-quality patients
in our study, means that the data quality should be
appropriate for this type of research. All prescriptions
are identifiable by using British National Formulary
and Gemscript coding, as well as drug name, allowing
accurate classification of all diabetes medications into
their respective classes. Because CPRD includes
primary care data only, we do not have information
on prescriptions from secondary or private care.
However, because T2DM medications are
prescription only and predominantly prescribed in
primary care, there is likely to be minimal
misclassification of the drugs prescribed. Two clinical
experts validated the codes used in this study,
including those used to identify the patient cohort and
CVD history, to ensure these were accurate. Although
we do not have data on whether the prescription was
collected or taken, the record represents the
physician's decision to treat, which is the relevant
measure for this study. It is possible that prescribing
at our cross-section dates (beginning of January or
end of December) could be affected by the Christmas
period; however, sensitivity analyses showed that
varying definitions, including a simple definition of
any prescription in the previous 3 months, made little
difference to the results, suggesting that the impact of
disruption is likely to be limited.
As discussed earlier, the present study was not
designed to identify the factors behind prescribing
decisions, which may include formulary and guideline
restrictions, or numerous clinical variables such as
body mass index, achievement of glycemic targets,
renal function, or other individual contraindications.
These factors are important in understanding how
prescribing may be optimized in the United Kingdom
and are the subject of ongoing work.
Some patient characteristics are known to be poorly
completed in CPRD, notably ethnicity, with ~50%
missing data in our study. The coronavirus disease
2019 pandemic, and in particular the increased risk
of poorer outcomes in those in Black, Asian, and
minority ethnic groups, has shown the importance of
this type of information, which is sometimes
considered to be of secondary importance when
completing data records. The proportions of missing13
Clinical Therapeuticsdata have been recorded for transparency in our study;
however, because the effect of these characteristics is
not being directly analyzed, this is unlikely to change
the conclusions of this analysis.CONCLUSIONS
Overall and early use (ie, monotherapy and dual
therapy) of SGLT2 inhibitors and GLP1-RAs remains
low, and there seems to be some country-level
variation in usage, despite broadly similar trends over
time. Although use of these classes, particularly
SGLT2 inhibitors, is increasing, they are currently
used slightly less in people with a history of CVD
despite this group being likely to benefit. Although
further investigations into drivers of class choice are
warranted, it is likely that further opportunity
remains to optimize use of these treatments to
manage CVD risk as well as glycemic control in
patients with T2DM.CONFLICTS OF INTEREST
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